MK-8189
Phase 1Small molecule
Merck & Co.MK-8189 is one of 80 small molecule programs targeting Bipolar I Disorder. It is currently in Phase 1.
3
Indications
12
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Celexa
AbbViePreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Depakote
AbbViePreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Inversine
TTargacept Inc.
Preclinical
Permax
VValeant Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Schizophrenia8 trials
Show 5 more trials
Hepatic Impairment1 trial
Absorption1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-8189. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company